Delivery Order 36F79718D0405-36C25923F0317
Award Date 5/26/23
Potential Completion Date 6/26/23
Potential Value $313K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Bristol-Myers Squibb Company was awarded a delivery order against its Pharmaceuticals and Drugs Federal Supply Schedule contract to provide $313,394.97 worth of BREYANZI to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19. BREYANZI is a chimeric antigen receptor T cell immunotherapy used to treat certain types of non-Hodgkin lymphoma. The delivery order was issued on a firm fixed price basis and has a period of performance through October...
- <p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA - VHA) awarded a $313,394.97 delivery order contract to Bristol-Myers Squibb Company Bristol Myers Squibb Division for the provision of BREYANZI. The prime contractor, Bristol-Myers Squibb Company, will perform under its Pharmaceuticals and Drugs Federal Supply Schedule contract. The firm fixed price order has a period of performance from January 30, 2023 through March 7, 2023.</p>
- <p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA - VHA) awarded Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, a $312,730.81 delivery order under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. Bristol-Myers Squibb will provide BREYANZI, an oncology treatment, to the VA from March 22, 2022 through April 19, 2022. The contract utilizes a firm fixed price payment structure.</p>
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Bristol-Myers Squibb Company under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy. The $310,935.67 firm-fixed price award has a period of performance through May 10, 2024, with all work to be performed in Lawrenceville, New Jersey. No set-aside designation was used...
- The U.S. Department of Veterans Affairs (VA) awarded a firm-fixed-price delivery order contract to Bristol-Myers Squibb Company for the procurement of the cancer immunotherapy drug BREYANZI. The contract, valued at $335,042.65, has an ultimate completion date of May 14, 2025 and is placed under the company's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA. This contract does not carry a set-aside designation, reflecting Bristol-Myers Squibb's status as a large...
- This is a federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, for its BREYANZI chimeric antigen receptor (CAR) T cell therapy. The $310,935.67 firm fixed price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 and has an ultimate completion date of October 31, 2024. The award is not a set-aside contract. Bristol-Myers Squibb supplies the BREYANZI treatment, which is used to treat...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to patient ENR-018564. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9). The contract is a firm fixed price delivery order with a ceiling value of $310,935.67 and a performance period ending on January 5, 2025. This order is placed against...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to the U.S. Department of Veterans Affairs (VA). The contract, valued at $310,953.57, was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on December 13, 2024. The work is primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey, and the delivery order has a completion date of January 12, 2025. This award is a delivery order...
- This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy product, to the Department of Veterans Affairs (VA) for the treatment of a veteran patient. The contract was awarded to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, and has a ceiling value of $335,042.65. The contract is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA,...
- This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer. The contract, valued at $670,085.30, is for the delivery of the emergency cancer therapy BREYANZI infusion. It is part of a larger Federal Supply Schedule (FSS) contract between the VA and Bristol-Myers Squibb, valued at $12,278,876,570.00 and running through April 2029. The FSS contract covers a range of pharmaceutical...